NXDT

SEC source: 0001437749-24-011455 · rdgdoc.xml · derivative · entry 4

Mitts Brian · CIK 0001514845 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,388

Underlying: Common Shares · 7,463 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 29,851 restricted shares units which vested one-fourth on April 4, 2024, and will vest one-fourth on April 4, 2025, one-fourth on April 4, 2026 and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 29,851 restricted shares units which vested one-fourth on April 4, 2024, and will vest one-fourth on April 4, 2025, one-fourth on April 4, 2026 and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-011455 · rdgdoc.xml · nonDerivative · entry 2

Mitts Brian · CIK 0001514845 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,987

SEC source: 0001437749-24-011455 · rdgdoc.xml · nonDerivative · entry 1

Mitts Brian · CIK 0001514845 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

SEC source: 0001437749-24-011452 · rdgdoc.xml · derivative · entry 2

Swain Carol · CIK 0001941224 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 7,463 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which vested on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which vested on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-011452 · rdgdoc.xml · nonDerivative · entry 1

Swain Carol · CIK 0001941224 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,463

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

SEC source: 0001437749-24-011453 · rdgdoc.xml · derivative · entry 3

Sauter Dennis Charles Jr · CIK 0001803863 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,462

Underlying: Common Shares · 2,488 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 9,950 restricted shares units which vested one-fourth on April 4, 2024, and will vest one-fourth on April 4, 2025, one-fourth on April 4, 2026 and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 9,950 restricted shares units which vested one-fourth on April 4, 2024, and will vest one-fourth on April 4, 2025, one-fourth on April 4, 2026 and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-011453 · rdgdoc.xml · nonDerivative · entry 2

Sauter Dennis Charles Jr · CIK 0001803863 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,677

SEC source: 0001437749-24-011453 · rdgdoc.xml · nonDerivative · entry 1

Sauter Dennis Charles Jr · CIK 0001803863 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,488

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

SEC source: 0001437749-24-011451 · rdgdoc.xml · derivative · entry 2

Wood Catherine D. · CIK 0001820212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 7,463 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which vested on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which vested on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-011451 · rdgdoc.xml · nonDerivative · entry 1

Wood Catherine D. · CIK 0001820212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

SEC source: 0001437749-24-008529 · rdgdoc.xml · derivative · entry 1

LAFFER ARTHUR B · CIK 0001090307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,698

Underlying: Common Shares · 11,698 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008526 · rdgdoc.xml · derivative · entry 1

NORRIS DUSTIN DAVID · CIK 0001617176 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,429

Underlying: Common Shares · 71,429 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 71,429 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 71,429 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008534 · rdgdoc.xml · derivative · entry 1

Constantino Edward N. · CIK 0001498322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,698

Underlying: Common Shares · 11,698 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008533 · rdgdoc.xml · derivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 292,500

Underlying: Common Shares · 292,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 292,500 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 292,500 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008532 · rdgdoc.xml · derivative · entry 1

KAVANAUGH SCOTT F · CIK 0001218975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,698

Underlying: Common Shares · 11,698 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008528 · rdgdoc.xml · derivative · entry 1

McGraner Matt · CIK 0001636187 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 292,500

Underlying: Common Shares · 292,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 292,500 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 292,500 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008527 · rdgdoc.xml · derivative · entry 1

Mitts Brian · CIK 0001514845 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,429

Underlying: Common Shares · 21,429 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 21,429 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 21,429 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008525 · rdgdoc.xml · derivative · entry 1

Sauter Dennis Charles Jr · CIK 0001803863 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,714

Underlying: Common Shares · 10,714 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 10,714 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 10,714 restricted shares units. The restricted shares units will vest one-fourth on March 18, 2025, one-fourth on March 18, 2026, one-fourth on March 18, 2027, and one-fourth on March 18, 2028. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008524 · rdgdoc.xml · derivative · entry 1

Swain Carol · CIK 0001941224 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,698

Underlying: Common Shares · 11,698 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-008523 · rdgdoc.xml · derivative · entry 1

Wood Catherine D. · CIK 0001820212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,698

Underlying: Common Shares · 11,698 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On March 18, 2024, the reporting person was granted 11,698 restricted shares units which will vest on March 18, 2025. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-24-001561 · rdgdoc.xml · nonDerivative · entry 3

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 597,203.68

F5 · kind: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 56,455.49 common shares to the Adviser as payment of its fees for the month of December at a VWAP of $7.9779.

F5 · price: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 56,455.49 common shares to the Adviser as payment of its fees for the month of December at a VWAP of $7.9779.

F3 · ownership.nature: 32,082 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 69,294.07 shares are held by PCMG Trading Partners XXIII, L.P., 180,159 shares are held by Governance Re Ltd. and 315,668.61 shares (following the acquisitions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-24-001561 · rdgdoc.xml · nonDerivative · entry 2

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 540,748.19

F4 · kind: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 55,617.45 common shares to the Adviser as payment of its fees for the month of November at a VWAP of $8.2637 per share.

F4 · price: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 55,617.45 common shares to the Adviser as payment of its fees for the month of November at a VWAP of $8.2637 per share.

F3 · ownership.nature: 32,082 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 69,294.07 shares are held by PCMG Trading Partners XXIII, L.P., 180,159 shares are held by Governance Re Ltd. and 315,668.61 shares (following the acquisitions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-24-001561 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 485,130.74

F1 · kind: Under the terms of the Advisory Agreement, dated July 1, 2022, by and between NexPoint Diversified Real Estate Trust (the "Company") and NexPoint Real Estate Advisers X, L.P. (the "Adviser"), as amended by that First Amendment to Advisory Agreement dated October 25, 2022, and as amended by that Second Amendment to Advisory Agreement, dated April 11, 2023 (the "Advisory Agreement"), the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the volume-weighted average price ("VWAP") of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 57,847.68 common shares to the Adviser as payment of its fees for the month of October at a VWAP of $7.7859 per share.

F1 · price: Under the terms of the Advisory Agreement, dated July 1, 2022, by and between NexPoint Diversified Real Estate Trust (the "Company") and NexPoint Real Estate Advisers X, L.P. (the "Adviser"), as amended by that First Amendment to Advisory Agreement dated October 25, 2022, and as amended by that Second Amendment to Advisory Agreement, dated April 11, 2023 (the "Advisory Agreement"), the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the volume-weighted average price ("VWAP") of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 57,847.68 common shares to the Adviser as payment of its fees for the month of October at a VWAP of $7.7859 per share.

F2 · balance_after: Includes shares acquired under a dividend reinvestment plan.

F3 · ownership.nature: 32,082 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 69,294.07 shares are held by PCMG Trading Partners XXIII, L.P., 180,159 shares are held by Governance Re Ltd. and 315,668.61 shares (following the acquisitions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-029242 · rdgdoc.xml · nonDerivative · entry 3

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 423,460.67

F4 · kind: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 55,161.78 common shares to the Adviser as payment of its fees for the month of September at a VWAP of $8.7226.

F4 · price: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 55,161.78 common shares to the Adviser as payment of its fees for the month of September at a VWAP of $8.7226.

F2 · ownership.nature: 32,082 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 67,819.68 shares are held by PCMG Trading Partners XXIII, L.P., 177,811 shares are held by Governance Re Ltd. and 145,747.99 shares (following the acquisitions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-029242 · rdgdoc.xml · nonDerivative · entry 2

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 368,298.89

F3 · kind: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 49,143.08 common shares to the Adviser as payment of its fees for the month of August at a VWAP of $9.8562 per share.

F3 · price: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 49,143.08 common shares to the Adviser as payment of its fees for the month of August at a VWAP of $9.8562 per share.

F2 · ownership.nature: 32,082 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 67,819.68 shares are held by PCMG Trading Partners XXIII, L.P., 177,811 shares are held by Governance Re Ltd. and 145,747.99 shares (following the acquisitions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-029242 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 319,155.81

F1 · kind: Under the terms of the Advisory Agreement, dated July 1, 2022, by and between NexPoint Diversified Real Estate Trust (the "Company") and NexPoint Real Estate Advisers X, L.P. (the "Adviser"), as amended by that First Amendment to Advisory Agreement dated October 25, 2022, and as amended by that Second Amendment to Advisory Agreement, dated April 11, 2023 (the "Advisory Agreement"), the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the volume-weighted average price ("VWAP") of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 26,726.38 common shares to the Adviser as payment of its fees for the month of July at a VWAP of $12.3099 per share.

F1 · price: Under the terms of the Advisory Agreement, dated July 1, 2022, by and between NexPoint Diversified Real Estate Trust (the "Company") and NexPoint Real Estate Advisers X, L.P. (the "Adviser"), as amended by that First Amendment to Advisory Agreement dated October 25, 2022, and as amended by that Second Amendment to Advisory Agreement, dated April 11, 2023 (the "Advisory Agreement"), the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the volume-weighted average price ("VWAP") of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 26,726.38 common shares to the Adviser as payment of its fees for the month of July at a VWAP of $12.3099 per share.

F2 · ownership.nature: 32,082 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 67,819.68 shares are held by PCMG Trading Partners XXIII, L.P., 177,811 shares are held by Governance Re Ltd. and 145,747.99 shares (following the acquisitions described herein) are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-027967 · rdgdoc.xml · nonDerivative · entry 2

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 20,797

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-027967 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 20,424

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-024070 · rdgdoc.xml · nonDerivative · entry 1

KAVANAUGH SCOTT F · CIK 0001218975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001437749-23-021968 · rdgdoc.xml · nonDerivative · entry 2

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 288,509.53

F3 · kind: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 6,808.31 common shares to the Adviser as payment of its fees for the month of June at a VWAP of $11.493 per share.

F3 · price: Under the terms of the Advisory Agreement, the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the VWAP of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 6,808.31 common shares to the Adviser as payment of its fees for the month of June at a VWAP of $11.493 per share.

F2 · ownership.nature: 31,556 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 66,584.78 shares are held by PCMG Trading Partners XXIII, L.P., 175,780 shares are held by Governance Re Ltd. and 14,588.75 are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-021968 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 281,701.22

F1 · kind: Under the terms of the Advisory Agreement, dated July 1, 2022, by and between NexPoint Diversified Real Estate Trust (the "Company") and NexPoint Real Estate Advisers X, L.P. (the "Adviser"), as amended by that First Amendment to Advisory Agreement dated October 25, 2022, and as amended by that Second Amendment to Advisory Agreement, dated April 11, 2023 (the "Advisory Agreement"), the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the volume-weighted average price ("VWAP") of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 7,780.44 common shares to the Adviser as payment of its fees for the month of May at a VWAP of $10.057 per share.

F1 · price: Under the terms of the Advisory Agreement, dated July 1, 2022, by and between NexPoint Diversified Real Estate Trust (the "Company") and NexPoint Real Estate Advisers X, L.P. (the "Adviser"), as amended by that First Amendment to Advisory Agreement dated October 25, 2022, and as amended by that Second Amendment to Advisory Agreement, dated April 11, 2023 (the "Advisory Agreement"), the Adviser may elect to receive payment for a portion of its monthly fees under the Advisory Agreement in common shares of the Company. Such common shares received as payment are valued at the volume-weighted average price ("VWAP") of the shares for the 10 trading days prior to the end of the month for which such fees will be paid. The Company issued 7,780.44 common shares to the Adviser as payment of its fees for the month of May at a VWAP of $10.057 per share.

F2 · ownership.nature: 31,556 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 66,584.78 shares are held by PCMG Trading Partners XXIII, L.P., 175,780 shares are held by Governance Re Ltd. and 14,588.75 are held by the Adviser. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-017066 · rdgdoc.xml · nonDerivative · entry 1

Wood Catherine D. · CIK 0001820212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

SEC source: 0001437749-23-016368 · rdgdoc.xml · nonDerivative · entry 2

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 18,343

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-016368 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 16,946

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-016107 · rdgdoc.xml · nonDerivative · entry 2

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 16,541

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-016107 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 16,532

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015991 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 16,032

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015731 · rdgdoc.xml · nonDerivative · entry 7

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,852

F5 · ownership.nature: These shares are held by Drugcrafters. Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015731 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 273,050.39

F1 · ownership.nature: 31,556 shares are held by Drugcrafters, L.P. ("Drugcrafters"), 65,714.39 shares are held by PCMG Trading Partners XXIII, L.P. and 175,780 shares are held by Governance Re Ltd. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015469 · rdgdoc.xml · nonDerivative · entry 7

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 269,505.39

F4 · ownership.nature: 28,011 shares are held by Drugcrafters, 65,714.39 shares are held by PCMG Trading Partners XXIII, L.P. and 175,780 shares are held by Governance Re Ltd. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015469 · rdgdoc.xml · nonDerivative · entry 2

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,411

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015469 · rdgdoc.xml · nonDerivative · entry 6

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 255,076.39

F4 · ownership.nature: 28,011 shares are held by Drugcrafters, 65,714.39 shares are held by PCMG Trading Partners XXIII, L.P. and 175,780 shares are held by Governance Re Ltd. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015469 · rdgdoc.xml · nonDerivative · entry 5

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 250,052.39

F4 · ownership.nature: 28,011 shares are held by Drugcrafters, 65,714.39 shares are held by PCMG Trading Partners XXIII, L.P. and 175,780 shares are held by Governance Re Ltd. Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of shares held by such entities. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-015469 · rdgdoc.xml · nonDerivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,206

F1 · ownership.nature: These shares are held by Drugcrafters, L.P. ("Drugcrafters"). Mr. Dondero is the sole managing member of the general partner of Drugcrafters and may be deemed to be an indirect beneficial owner of shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001437749-23-009650 · rdgdoc.xml · derivative · entry 1

LAFFER ARTHUR B · CIK 0001090307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,463

Underlying: Common Shares · 7,463 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which will vest on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which will vest on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-23-009654 · rdgdoc.xml · derivative · entry 1

NORRIS DUSTIN DAVID · CIK 0001617176 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,751

Underlying: Common Shares · 49,751 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 49,751 restricted shares units. The restricted shares units will vest one-fourth on April 4, 2024, one-fourth on April 4, 2025, one-fourth on April 4, 2026, and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 49,751 restricted shares units. The restricted shares units will vest one-fourth on April 4, 2024, one-fourth on April 4, 2025, one-fourth on April 4, 2026, and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-23-009648 · rdgdoc.xml · derivative · entry 1

Constantino Edward N. · CIK 0001498322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,463

Underlying: Common Shares · 7,463 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which will vest on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which will vest on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-23-009659 · rdgdoc.xml · derivative · entry 1

DONDERO JAMES D · CIK 0001228922 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,662

Underlying: Common Shares · 187,662 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 187,662 restricted shares units. The restricted shares units will vest one-fourth on April 4, 2024, one-fourth on April 4, 2025, one-fourth on April 4, 2026, and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 187,662 restricted shares units. The restricted shares units will vest one-fourth on April 4, 2024, one-fourth on April 4, 2025, one-fourth on April 4, 2026, and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-23-009649 · rdgdoc.xml · derivative · entry 1

KAVANAUGH SCOTT F · CIK 0001218975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,463

Underlying: Common Shares · 7,463 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which will vest on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 7,463 restricted shares units which will vest on April 4, 2024. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

SEC source: 0001437749-23-009658 · rdgdoc.xml · derivative · entry 1

McGraner Matt · CIK 0001636187 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,498

Underlying: Common Shares · 180,498 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted shares unit represents a contingent right to receive one common share of NexPoint Diversified Real Estate Trust.

F2 · derivative.exercise_date: On April 4, 2023, the reporting person was granted 180,498 restricted shares units. The restricted shares units will vest one-fourth on April 4, 2024, one-fourth on April 4, 2025, one-fourth on April 4, 2026, and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.

F2 · derivative.expiration_date: On April 4, 2023, the reporting person was granted 180,498 restricted shares units. The restricted shares units will vest one-fourth on April 4, 2024, one-fourth on April 4, 2025, one-fourth on April 4, 2026, and one-fourth on April 4, 2027. Settlement will generally occur within 10 days of vesting and may at the discretion of the Compensation Committee be settled in cash.